
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3869793/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in <i>RUNX1</i> deficiency. Blood Advances, 2022, 6, 5100-5112.	2.5	3
2	Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 585-591.e2.	0.9	29
3	Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (Simvastatin in the) Tj ETQq1	1 0.78431 1.9	.4 rgBT /Ove
4	Coagulation markers and functional outcome in acute ischemic stroke: Impact of intensive versus standard hyperglycemia control. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12563.	1.0	0
5	Gray platelet syndrome: immunity goes awry. Blood, 2020, 136, 1898-1900.	0.6	2
6	Inherited Platelet Defects and Mutations in Hematopoietic Transcription Factor RUNX1. , 2019, , 317-325.		0
7	Platelet Function in Hemostasis and Inherited Disorders of Platelet Number and Function. , 2019, , 123-134.		0
8	Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor. Blood Advances, 2018, 2, 797-806.	2.5	17
9	Dysregulation of PLDN (pallidin) is a mechanism for platelet dense granule deficiency in RUNX1 haplodeficiency. Journal of Thrombosis and Haemostasis, 2017, 15, 792-801.	1.9	21
10	Editorial: Platelet Genomics and Disorders of Platelet Number and Function. Platelets, 2017, 28, 2-2.	1.1	2
11	Hematopoietic transcription factor mutations: important players in inherited platelet defects. Blood, 2017, 129, 2873-2881.	0.6	48
12	Defective acid hydrolase secretion in <i><scp>RUNX</scp>1</i> haplodeficiency: Evidence for a global platelet secretory defect. Haemophilia, 2017, 23, 784-792.	1.0	13
13	Parsing the repertoire of GPIb-IX-V disorders. Blood, 2017, 129, 403-404.	0.6	8
14	Transcription Factor RUNX1 Regulates Platelet <i>PCTP</i> (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events. Circulation, 2017, 136, 927-939.	1.6	18
15	Inherited platelet dysfunction and hematopoietic transcription factor mutations. Platelets, 2017, 28, 20-26.	1.1	13
16	Nuclear factor-κB regulates expression of platelet phospholipase C-β2 (PLCB2). Thrombosis and Haemostasis, 2016, 116, 931-940.	1.8	9
17	Platelet disorders: the next generation is in. Blood, 2016, 127, 2781-2782.	0.6	2
18	Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. EBioMedicine, 2016, 11, 157-164.	2.7	19

#	Article	IF	CITATIONS
19	P2Y12 receptor inhibition and LPS-induced coagulation. Clinical Science, 2016, 130, 441-442.	1.8	2
20	PCTP (Phosphatidylcholine Transfer Protein) is Regulated By RUNX1 in Platelets/Megakaryocytes and is Associated with Adverse Cardiovascular Events. Blood, 2016, 128, 365-365.	0.6	2
21	Inherited thrombocytopenias: the beat goes on. Blood, 2015, 125, 748-750.	0.6	6
22	Tissue factor and Toll-like receptor (TLR)4 in hyperglycaemia-hyperinsulinaemia. Thrombosis and Haemostasis, 2015, 113, 750-758.	1.8	21
23	Hematopoietic transcription factor mutations and inherited platelet dysfunction. F1000prime Reports, 2015, 7, 66.	5.9	18
24	Transcription Factor RUNX1 Regulates Pctp (Phosphatidylcholine Transfer Protein) in Platelets: A Potential Role in Regulating Platelet Function. Blood, 2015, 126, 2247-2247.	0.6	6
25	Alterations in insulin-signaling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject. Thrombosis Research, 2014, 134, 704-710.	0.8	17
26	Preface. Hematology/Oncology Clinics of North America, 2013, 27, xiii-xiv.	0.9	0
27	Inherited Platelet Function Disorders. Hematology/Oncology Clinics of North America, 2013, 27, 585-611.	0.9	36
28	Spotlight on FLI1, RUNX1, and platelet dysfunction. Blood, 2013, 122, 4004-4006.	0.6	7
29	A procoagulant state and endothelial dysfunction in obese children - response to Blann. British Journal of Haematology, 2013, 160, 718-719.	1.2	Ο
30	Whole-Blood Tissue Factor Procoagulant Activity Is Elevated in Type 1 Diabetes. Diabetes Care, 2012, 35, 1322-1327.	4.3	22
31	Elevated circulating tissue factor procoagulant activity, factor <scp>VII</scp> , and plasminogen activator inhibitorâ€1 in childhood obesity: evidence of a procoagulant state. British Journal of Haematology, 2012, 158, 523-527.	1.2	30
32	Divergent Effect of Insulin On Whole-Blood Tissue Factor Procoagulant Activity in the Presence and Absence of Lipopolysaccharide. Blood, 2012, 120, 636-636.	0.6	2
33	Alterations in Insulin-Signaling and Coagulation Pathways in Platelets During Hyperglycemia-Hyperinsulinemia. Blood, 2012, 120, 633-633.	0.6	0
34	Mechanism of platelet factorÂ4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of. Journal of Thrombosis and Haemostasis, 2011, 9, 383-391.	1.9	42
35	Platelet Protein Kinase C-Î, Deficiency With Human RUNX1 Mutation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 921-927.	1.1	26
36	RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood, 2010, 115, 3128-3135.	0.6	65

#	Article	IF	CITATIONS
37	Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood, 2010, 116, 6037-6045.	0.6	70
38	A Novel 3-Base Pair 1834–1836 AAG-Deletion (Lys570Del) Mutation In Factor XIII A Subunit Associated with Factor XIII Deficiency. Blood, 2010, 116, 1412-1412.	0.6	0
39	Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thrombosis Research, 2009, 124, 259-261.	0.8	56
40	Mechanism of Platelet Factor (PF4) Deficiency with RUNX1 Mutations: RUNX1 Is a Transcriptional Regulator of PF4 Blood, 2009, 114, 227-227.	0.6	4
41	Platelet/Megakaryocyte PKC-Î~ Is a Transcriptional Target of RUNX1/ CBFA2: Studies in Human RUNX1 Haplodeficiency Blood, 2008, 112, 1846-1846.	0.6	1
42	RUNX1/CBFA2 Regulates Myosin Light Chain 9 (MYL9) in Megakaryocytic Cells: Decreased MYL9 Expression in Human RUNX1 Haplodeficiency Blood, 2008, 112, 1831-1831.	0.6	0
43	Circulating Tissue Factor Procoagulant Activity and Thrombin Generation in Patients with Type 2 Diabetes: Effects of Insulin and Glucose. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4352-4358.	1.8	120
44	Alternative splice variants of phospholipase C-β2 are expressed in platelets: Effect on Gαq-dependent activation and localization. Platelets, 2007, 18, 217-223.	1.1	16
45	Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: Impact of hyperglycemia. Thrombosis and Haemostasis, 2007, 98, 1007-1013.	1.8	46
46	Decreased platelet expression of myosin regulatory light chain polypeptide (MYL9) and other genes with platelet dysfunction and CBFA2/RUNX1 mutation: insights from platelet expression profiling. Journal of Thrombosis and Haemostasis, 2007, 5, 146-154.	1.9	73
47	Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets, 2006, 17, 577-585.	1.1	82
48	Platelet function analyzer (PFA)-100R closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1432-1432.	1.9	9
49	Platelet function analyzer (PFA)-100Rclosure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1433-1434.	1.9	12
50	Early growth response transcription factor EGR-1 regulates Gαq gene in megakaryocytic cells. Journal of Thrombosis and Haemostasis, 2006, 4, 2678-2686.	1.9	26
51	Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes, 2006, 55, 202-8.	0.3	69
52	Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thrombosis and Haemostasis, 2006, 96, 738-43.	1.8	13
53	Decreased platelet Mpl receptor in AML1 haplodeficiency: another piece of the puzzle. Blood, 2005, 105, 4545-4545.	0.6	0
54	Inherited Defects in Platelet Signaling Mechanisms. Seminars in Thrombosis and Hemostasis, 2004, 30, 525-535.	1.5	55

#	Article	IF	CITATIONS
55	Molecular and biochemical basis for the platelet dysfunction in myeloproliferative disorders. Seminars in Hematology, 2004, 41, 6-9.	1.8	60
56	Association of CBFA2 mutation with decreased platelet PKC-Î, and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood, 2004, 103, 948-954.	0.6	78
57	Inherited defects in platelet signaling mechanisms. Journal of Thrombosis and Haemostasis, 2003, 1, 671-681.	1.9	56
58	Combined defect in membrane expression and activation of platelet GPIIb–IIIa complex without primary sequence abnormalities in myeloproliferative disease. British Journal of Haematology, 2000, 111, 954-964.	1.2	8
59	Congenital Disorders of Platelet Signal Transduction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 285-289.	1.1	34
60	Inhibition of Tissue Factor Pathway During Intermittent Pneumatic Compression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2812-2817.	1.1	57
61	Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thrombosis and Haemostasis, 1999, 82, 140-4.	1.8	3
62	Inherited thrombophilic states. Seminars in Thrombosis and Hemostasis, 1998, 24 Suppl 1, 3-12.	1.5	3
63	Simultaneous Occurrence of Human Antibodies Directed against Fibrinogen, Thrombin, and Factor V Following Exposure to Bovine Thrombin: Effects on Blood Coagulation, Protein C Activation and Platelet Function. Thrombosis and Haemostasis, 1997, 77, 343-349.	1.8	63
64	Impaired Platelet Aggregation and Abnormal Activation of GPIIb-IIIa. Thrombosis and Haemostasis, 1997, 78, 1302-1302.	1.8	5
65	Nafamostat Mesilate, a Broad Spectrum Protease Inhibitor, Modulates Platelet, Neutrophil and Contact Activation in Simulated Extracorporeal Circulation. Thrombosis and Haemostasis, 1996, 75, 076-082.	1.8	53
66	Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood, 1996, 87, 1368-76.	0.6	18
67	Mechanisms of Platelet Dysfunction and Response to DDAVP in Patients with Congenital Platelet Function Defects. Thrombosis and Haemostasis, 1995, 74, 1071-1078.	1.8	58
68	A Comparison of the Effect of Decorsin and Two Disintegrins, Albolabrin and Eristostatin, on Platelet Function. Thrombosis and Haemostasis, 1995, 74, 1316-1322.	1.8	15
69	Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial. Thrombosis and Haemostasis, 1995, 74, 1071-8.	1.8	7
70	Factor XI deficiency and hemostasis. American Journal of Hematology, 1994, 45, 73-78.	2.0	11
71	Warfarin skin necrosis in a 33-year-old woman. American Journal of Hematology, 1993, 43, 300-303.	2.0	10
72	Clinical studies in hemostasis and thrombosis at Temple University School of Medicine. Platelet bleeding disorder in a 30-year-old female. mechanisms of congenital platelet function defects. American Journal of Hematology, 1993, 44, 139-144.	2.0	4

#	Article	IF	CITATIONS
73	Clinical studies in hemostasis and thrombosis at Temple University school of medicine. Refractory thrombocytopenia in a 27-year-old female following allogeneic bone marrow transplantation. American Journal of Hematology, 1993, 44, 284-288.	2.0	7
74	Congenital disorders of platelet function. Hematology/Oncology Clinics of North America, 1990, 4, 65-86.	0.9	7
75	Low incidence of thrombocytopenia with porcine mucosal heparin. A prospective multicenter study. Archives of Internal Medicine, 1989, 149, 1285-8.	4.3	2
76	Impaired cytoplasmic ionized calcium mobilization in inherited platelet secretion defects. Blood, 1989, 74, 664-72.	0.6	5
77	Differential requirements for platelet aggregation and inhibition of adenylate cyclase by epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect. Blood, 1988, 71, 494-501.	0.6	5
78	Platelet-activating factor is a weak platelet agonist: Evidence from normal human platelets and platelets with congenital secretion defects. American Journal of Hematology, 1984, 17, 153-165.	2.0	15
79	Platelet secretion defect in patients with the attention deficit disorder and easy bruising. Blood, 1984, 63, 427-33.	0.6	3